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1. Introduction 
Excessive alcohol consumption causes a variety of liver diseases including alcoholic 
steatosis, alcoholic hepatitis (AH), liver fibrosis, cirrhosis and hepatocellular carcinoma 
(Mandayam et al. 2004). Alcoholic steatosis is, generally, a benign lesion if the patient 
abstains from alcohol intake, whereas AH observed in the approximately 20% of heavy 
drinkers is much more serious and requires treatment with the development of 
hepatocellular necrosis and inflammation (Menon et al., 2001). The severe form of AH, 
severe alcoholic hepatitis (SAH), is characterized by multiorgan failure with manifestations 
of acute hepatic failure and is associated with high morbidity and mortality (Haber et al., 
2003; Ishii et al., 1993; Maddrey et al., 1978; Mookerjee et al., 2003; Sougioultzis, 2005). 
Alcohol-induced liver injury (ALD) occurs through the multiple steps involving a range 
from innate immune cells to the liver parenchymal cells, and out of many factors 
contributing to the pathogenesis of ALD gut-derived endotoxin plays a central role in the 
induction of steatosis, inflammation, and fibrosis in the liver (Bode & Bode, 2005; Fukui et 
al., 1991; Mandrekar & Szabo, 2009; McClain et al, 2005; Nolan, 2010; Vidali et al., 2008). AH 
is a multifactorial process involving gut-derived endotoxin-induced Kupffer cell activation 
via hepatic reticuloendothelial dysfunction and increased intestinal permeability, and 
subsequent cytokine stimulation. Additional factors include ethanol metabolism to toxic 
products, oxidative stress, acetaldehyde adducts, nutritional impairment and impaired 
hepatic regeneration (Haber et al., 2003; Ishii et al., 1993, Mookerjee et al., 2003; Nath & 
Szabo, 2009; Nolan, 2010; Sakaguchi et al., 2011; Sougioultzis et al., 2005; Tsukamoto et al., 
2009; Wu & Cederbaum, 2009). In SAH pathogenesis, endotoxemia may trigger enhanced 
pro-inflammatory cytokine production, potentially causing a systemic inflammatory 
response syndrome together with microcirculatory disturbances, systemic haemodynamic 
derangements, and subsequent multiorgan failure (Fukui, 2005; Haber et al., 2003; Ishii et 
al., 1993; Mookerjee et al., 2003; Sougioultzis et al., 2005).  
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ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 
13) is a metalloproteinase that specifically cleaves multimeric von Willebrand factor (VWF) 
between Tyr1605 and Met1606 residues in the A2 domain (Moake 2002; Fujimura et al., 
2002). In the absence of ADAMTS13 activity (ADAMTS13:AC), unusually large VWF 
multimers (UL-VWFMs) are released from vascular endothelial cells (ECs) and improperly 
cleaved, causing them to accumulate and to induce the formation of platelet thrombi in the 
microvasculature under conditions of high shear stress. Currently, a severe deficiency in 
ADAMTS13:AC, which results either from genetic mutations in the ADAMTS13 gene 
(Upshaw-Schulman syndrome, USS) (Fujimura et al., 2002; Kokame et al., 2002; Levy et al., 
2001, Moake, 2002) or acquired autoantibodies against ADAMTS13 (Furlan et al., 1998; Tsai 
& Lian, 1998), is thought to be a specific feature of thrombotic thrombocytopenic purpura 
(TTP) (Amorosi & Ultmann, 1966; Moschcowitz, 1924). 
In 2000, we demonstrated that a decreased plasma ADAMTS13:AC in patients with cirrhotic 
biliary atresia can be fully restored after liver transplantation, indicating that the liver is the 
main organ producing ADAMTS13 (Matsumoto et al., 2000). One year later, northern blot 
analysis showed that the 4.6-kilobase ADAMTS13 mRNA was highly expressed in the liver 
(Levy et al., 2001; Soejima, et al., 2001; Zheng et al., 2001), and subsequently both in situ 
hybridization and immunohistochemistry clearly indicated that ADAMTS13 is produced 
exclusively in hepatic stellate cells (HSCs) (Uemura et al., 2005a). Platelets (Suzuki et al., 
2004), vascular ECs (Turner et al., 2006), and kidney podocytes (Manea et al., 2007) also have 
been implicated as ADAMTS13-producing cells, but the amount produced by these cell 
types in the liver appears to be far less than that produced by HSCs.  
Mannucci et al. (Mannucci et al., 2001) originally reported a reduction of the ADAMTS13:AC 
in advanced liver cirrhosis (LC). Since HSCs were shown to be the major producing cells of 
ADAMTS13 in the liver (Uemura et al., 2005a), much attention has been paid to the potential 
role of ADAMTS13 in the pathophysiology of liver diseases associated with sinusoidal 
and/or systemic microcirculatory disturbances (Feys et al., 2007; Ishikawa et al., 2010; Ko et 
al., 2006; Kobayashi et al., 2009; Lisman et al., 2006; Matsuyama et al., 2007; Matsumoto et 
al., 2007; Okano et al., 2010; Park et al., 2002; Pereboom et al., 2009; Uemura et al., 2005b; 
Uemura et al., 2008a; Uemura et al., 2008b; Uemura et al., 2010; Yagita et al., 2005). 
ADAMTS13:AC is significantly decreased in patients with hepatic veno-occlusive disease 
(VOD) (Matsumoto et al., 2007; Park et al., 2002), AH (Ishikawa et al.,2010; Matsuyama et al., 
2007; Uemura et al., 2005b, Uemura et al., 2008b), LC (Feys et al., 2007; Uemura et al., 2008a), 
and patients undergoing living-donor related liver transplantation (Ko et al., 2006; 
Kobayashi et al.,2009; Pereboom et al., 2009) and partial hepatectomy (Okano et al.,2010).  
Furthermore, hepatitis C virus (HCV)-related LC patient with ADAMTS13 inhibitor 
(ADAMTS13:INH) typically develops TTP (Yagita et al., 2005). 
In this review, we will address interesting findings from our previous studies showing that 
plasma ADAMTS13:AC and its related parameters are potentially involved in the severity of 
liver disturbances and the development of multiorgan failure in patients with AH (Ishikawa 
et al., 2010; Matsuyama et al., 2007; Uemura et al., 2005b; Uemura et al., 2008b). We will 
focus on the importance of ADAMTS13 determination for a better understanding of 
pathophysiology and/or for possible therapeutic approaches of ADAMTS13 
supplementation in this disease. 
www.intechopen.com
Crucial Role of ADAMTS13 Related to Endotoxemia and  
Subsequent Cytokinemia in the Progression of Alcoholic Hepatitis 
 
181 
2. Alcohol-related thrombocytopenia and effects of alcohol on hemostasis 
Alcohol-related thrombocytopenia is independent of nutritional state or the presence of liver 
functional abnormalities, anemia, or leucopenia (Lindenbaum & Hargrove, 1968; Paintal et 
al., 1975; Post & Desforges, 1968a, 1968b; Rubin & Rand, 1994). Both quantitative and 
qualitative platelet abnormalities appear during alcohol consumption (Cowan, 1980). A 
decrease in circulating platelets was first reported in 3 alcoholics who responded to folic 
acid administration (Sullivan & Herbert, 1964). Subsequently, alcohol has been shown to 
exert a direct toxic effect on blood platelets in 5 chronic alcoholics with ten episodes of 
thrombocytopenia (Lindenbaum & Hargrove, 1968) and in 8 patients with acute alcoholism 
(Post & Desforges, 1968a), who showed no evidence of liver cirrhosis, splenomegaly, folate 
deficiency, or massive hemorrhage, indicating the presence of alcohol-related 
thrombocytopenia. Additionally, thrombocytopenia was observed in alcoholics on 
intravenous injection of ethanol (Post & Desforges, 1968b). The platelet counts in patients 
with alcohol-related thrombocytopenia return to normal quickly (2-3 days) after ingestion of 
ethanol is discontinued. Thereafter, the number of platelets increases, and maximum counts 
occur 5-21 days after cessation of alcohol (Cowan & Hines, 1971), when rebound 
thrombocytosis after alcohol abuse in some patients may contribute to thromboembolic 
disease (Haselager & Vreeken, 1977). Potential mechanisms for alcohol-related 
thrombocytopenia may involve a suppressive effect of alcohol on megakaryocyte 
maturation and platelet release (Sullivan & Herbert, 1964), reduced platelet survival time 
(Cowan, 1980), alterations of platelet structure (Cowan, 1980), and abnormalities of platelet 
metabolism involving adenosine nucleotides and eicosanoids (Cowan, 1980). The spectrum 
of platelet function defects in alcoholics is complex. In actively drinking alcoholic patients 
admitted to the hospital for detoxification, platelet aggregation in platelet-rich plasma is 
considerably reduced in response to agonists (Haut & Cowan, 1974; Neiman et al., 1989; 
Rubin & Rand, 1994), whereas platelet aggregation is greater in chronic alcoholics compared 
to normal healthy controls both on admission and 1 week after hospitalization (Arai et al., 
1986). It is necessary to clarify the role of platelet function not only in platelet aggregation in 
vitro, but also in platelet-endothelial interactions under shear stress during alcohol-related 
thrombocytopenia (Siegel-Axel & Gawaz, 2007). 
Alternatively, recent epidemiologic studies have consistently shown that regular light-to-
moderate alcohol intake protects against ischemic stroke including coronary heart disease 
and peripheral arterial disease (Camargo et al., 1997; Lippi et al., 2010; Mukamal et al., 2001; 
Rimm et al., 1996). Such beneficial effects may be attributable to a number of factors 
including the inhibition of platelet aggregation and adhesion, the decrease in plasma levels 
of VWF, fibrinogen, and coagulation factor VII, or the increase in nitric oxide bioavailability 
and high-density lipoprotein cholesterol (Lippi et al., 2010; Rubin R, 1999). In contrast, soft 
blood clots are often observed in cadaveric blood in cases of sudden death after excess 
alcohol consumption, which enhances the procoagulant status via VWF release, and IL-6-
related interaction with lipopolysaccharide (LPS) (Kasuda et al., 2009). Additionally, both 
chronic alcoholism and acute alcohol intoxication have increasingly been recognized as risk 
factors for circulatory disorders, including thrombotic complications and hemorrhage 
(Hillbom & Kaste, 1982; Hillbom & Kaste, 1983, Numminen et al., 2000). Patients with 
chronic alcoholism show a higher incidence of pulmonary infarction, cerebral infarction, and 
venous thrombosis in their extremities after abstinence (Haselager & Vreeken, 1977; Hillbom 
www.intechopen.com
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
182 
et al., 1985; Walbran et al., 1981), probably due to alterations of haemostatic and fibrinolytic 
parameters that may be largely influenced by drinking pattern, nutritional balance, and 
genetic background (Arai et al., 1986; Enomoto et al., 1991; Lippi et al., 2010; Mukamal et al., 
2001). 
3. Hepatic microcirculation and microcirculatory disturbances in ALD 
Hepatic microcirculation comprises a unique system of capillaries, called sinusoids, which 
are lined by three different cell types: sinusoidal endothelial cells (SECs), HSCs, and Kupffer 
cells (Kmieć, 2001). The SECs modulate microcirculation between hepatocytes and the 
sinusoidal space through the sinusoidal endothelial fenestration. The SECs have tremendous 
endocytic capacity, including for VWF and the extracellular matrix, and secrete many 
vasoactive substances (Kmieć, 2001). The HSCs are located in the space of Disse adjacent to 
the SECs, and regulates sinusoidal blood flow by contraction or relaxation induced by 
vasoactive substances (Rockey, 2001). Kupffer cells are intrasinusoidally-located tissue 
macrophages, and secrete potent inflammatory mediators during the early phase of liver 
inflammation (Kmieć, 2001). Intimate cell-to-cell interaction has been found between these 
sinusoidal cells and hepatocytes (Kmieć, 2001, Rockey, 2001). 
Vascular ESs play a pivotal role in hemostasis and thrombosis (Fujimura et al., 2002; Moake, 
2002). VWF is a marker of endothelial cell activation (damage), and plays an essential role in 
hemostasis (Fujimura et al., 2002; Moake, 2002). In the normal state, VWF immunostaining is 
usually positive in large vessels, but negative in the SECs (Hattori et al., 1991). On the 
occurrence of liver injury accompanied by a necroinflammatory process, the SECs become 
positive for VWF, presumably in association with the capillarization of hepatic sinusoids 
(Schaffner & Popper, 1963). Subsequently, platelets adhere to subendothelial tissue 
mediated by UL-VWFM. ADAMTS13 then cleaves UL-VWFM into smaller VWF multimers. 
This interaction of ADAMTS13 and UL-VWFM is the initial step in hemostasis (Fujimura, et 
al., 2002; Moake, 2002). 
Hepatic microcirculatory disturbances are considered to play an important pathogenic role 
in ALD. These disturbances include narrowing of the sinusoidal space due to ballooned 
hepatocytes and perisinusoidal fibrosis (French et al., 1984), imbalances between endothelin 
and nitric oxide (Oshita et al., 1993), and contraction of HSCs (Itatsu et al., 1988). After liver 
injury, fibrogenesis within the Disse’s space and a decrease in the number of sinusoidal 
endothelial fenestrations together with narrowing of their diameter may lead to 
neocapillarization of the endothelium (Horn et al., 1987; Mak & Lieber, 1984). Sinusoidal 
lining cells and the scar-parenchyma interface are stained by anti-VWF antibodies, even at 
the early stages of ALD (Urashima et al., 1993), indicating capillarization of the SECs. 
Interestingly, in SAH patients, mild to severe hepatic veno-occlusive disease (VOD) was 
frequently observed (Goodman & Ishak, 1982; Kishi et al., 2000), and the degree of ascites 
became more severe as VOD progressed (Kishi et al., 2000), suggesting that the hepatic 
circulatory disturbance involves not only the sinusoidal microcirculation but also the 
hepatic terminal veins. 
In patients with LC and fulminant hepatitis, VWF plasma levels are remarkably high 
(Albornoz et al., 1999; Ferro et al., 1996; Langley et al., 1985). In LC, immunostaining for 
VWF antigen (VWF:Ag) shows positive cells predominantly at the scar-parenchyma 
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interface, within the septum, and in the sinusoidal lining cells (Knittel, et al., 1995), and 
many fibrin thrombi are demonstrated in the hepatic sinusoid in patients with fulminant 
hepatitis (Rake et al., 1971), and in rats with dimethylnitrosamine (DMN) induced acute 
hepatic failure (Fujiwara et al., 1988). Portal or hepatic vein thrombosis is often observed in 
advanced LC (Amitrano et al., 2004; Wanless et al., 1995), and microthrombi formation is 
seen in one or multiple organs in one-half of autopsied cirrhotic patients (Oka & Tanaka, 
1979). Such a hypercoagulable state in liver diseases may be involved in hepatic 
parenchymal destruction, the acceleration of liver fibrosis and disease progression (Northup 
et al., 2008; Pluta et al., 2010). 
A deficiency of anticoagulant proteins (antithrombin, protein C and protein S) and the high 
levels of several procoagulant factors (Factor VIII and VWF) may contribute to 
hypercoagulability in advanced liver diseases (Northup et al., 2008). Locally, the SEC 
dysfunction could lead to the development of a hypercoagulable state at the hepatic 
sinusoids corresponding to the site of liver injury, even in the presence of a systemic 
hypocoagulable state (Northup et al., 2008). Considering that ADAMTS13 is synthesized in 
HSCs and its substrate, UL-VWFM, is produced in transformed SECs during liver injury, 
decreased plasma ADAMTS13:AC may involve not only sinusoidal microcirculatory 
disturbances, but also subsequent progression of liver diseases, finally leading to multiorgan 
failure. Based on these findings, it is of particular interest to evaluate the activity of plasma 
ADAMTS13:AC in patients with liver diseases including AH and SAH.  
4. Cleavage of UL-VWFM byADAMTS13 
Although the mechanism by which TTP develops in the absence of ADAMTS13:AC has not 
been fully elucidated, accumulating evidence has provided a hypothesis as illustrated in Fig. 
1. (Fujimura et al., 2008). UL-VWFMs are produced exclusively in vascular ECs and stored 
in an intracellular organelle termed Weidel-pallade bodies (WPBs) and then released into 
the circulation upon stimulation. Under physiological conditions, epinephrine acts as an 
endogenous stimulus, but under non-physiological conditions, DDAVP (1-deamino-8-D-
arginine vasopressin), hypoxia, and several cytokines such as interleukin IL-2, IL-6, IL-8 and 
tumor necrosis factor (TNFǂ) act as stimuli that up-regulate VWF release. Once ECs are 
stimulated, UL-VWFMs and P-selectin, both stored in WPBs, move to the membrane surface 
of ECs, where P-selectin anchors UL-VWFMs on the ECs surface (Padilla et al., 2004). Under 
these circumstances, high shear stress generated in the microvasculature induces a change in 
the UL-VWFM from a globular to an extended form (Siedlecki et al., 1996). The ADAMTS13 
protease efficiently cleaves the active extended form of UL-VWFM between the Tyr1605 and 
Met1606 residues in the A2 domain (Dent et al., 1990). In this context, it has been postulated 
that multiple exocites within the disintegrin-like/TSP1/cysteine-rich/spacer (DTCS) 
domains of ADAMTS13 play an important role in the interaction with the unfolded VWF-
A2 domain (Akiyama et al., 2009). ADAMTS13 may more efficiently cleave newly released 
UL-VWFMs that exist as solid-phase enzymes anchored to the vascular EC surface by 
binding to CD36, because CD36 is a receptor for TSP1, which is a repeated domain within 
the ADAMTS13 molecule (Davis et al., 2009). When ADAMTS13 activity is reduced, UL-
VWFM interacts more intensively with platelet GPIb and generates signals that further 
accelerate platelet activation (Fujimura et al., 2002; Moake, 2002) . A series of these reactions 
leads to platelet microaggregates and thrombocytopenia. However, little information has 
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been available on the cleavage of the UL-VWFMs by ADAMTS13 in the sinusoidal 
microcirculation in ALD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Proposed mechanism of platelet thrombi formation under high shear stress in the 
absence of ADAMTS13:AC. 
Unusually large von Willebrand factor multimers (UL-VWFMs) are produced in vascular 
endothelial cells (ECs) and stored in Weidel-pallade bodies (WPBs). UL-VWFMs are 
released from WPBs into the circulation upon stimulation by cytokines, hypoxia, DDAVP 
and epinephrine. P-selectin that co-migrates from WPBs anchors UL-VWFMs on the 
vascular EC surface. Under these circumstances, high shear stress changes the molecular 
conformation of UL-VWFMs from a globular to an extended form, allowing ADAMTS13 to 
access this molecule. In the absence of ADAMTS13:AC, UL-VWFMs remain uncleaved, 
allowing them to excessively interact with platelet glycoprotein (GP)Ibǂ and activate 
platelets via intra-platelet signaling, which result in the formation of platelet thrombi. 
Cytokines, endotoxin, and/or the inhibitor against ADAMTS13 may be candidates to 
decrease ADAMTS13 activity. (The dotted circle indicates a VWF subunit, which contains a 
set of binding domains with factor VIII, subendothelial collagen, platelet GPIbǂ, and 
integrin ǂIIbǃ3.) (Partially modified from Fujimura et al, 2008).  
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5. Assays for plasma ADAMTS13:AC and ADAMTS13:INH 
ADAMTS13:AC was determined with a classic VWFM assay in the presence of 1.5 mol/L 
urea using purified plasma derived VWF as a substrate, according to the method described 
by Furlan et al. (Furlan et al., 1996); the detection limit of this assay was 3% of the normal 
control in our laboratory (Kinoshita et al., 2001). In 2005, we developed a novel chromogenic 
ADAMTS13-act-ELISA using both an N- and C-terminal tagged recombinant VWF substrate 
(termed GST-VWF73-His). This assay was highly sensitive, and the detection limit was 0.5% 
of the normal control (Kato et al., 2006). Plasma ADAMTS13:AC levels highly correlated 
between VWFM assay and ADAMTS13-act-ELISA (Mean±SD, 102±23% vs. 99.1±21.5%, 
r2=0.72, p<0.01) (Kato et al., 2006) . No interference of the ADAMTS13-act-ELISA occurred 
even in the presence of hemoglobin, bilirubin or chylomicrons in the samples, thus enabling 
distinction from the FRETS-VWF73 assay (Kokame et., 2005; Meyer et al., 2007). Because of 
its high sensitivity, easy handling, and lack of interference from plasma components, the 
ADAMTS13-act-ELISA is recommended for routine laboratory use. 
The ADAMTS13:INH has also been evaluated with the chromogenic act-ELISA by means of 
the Bethesda method (Kasper et al., 1975). Prior to the assay, the test samples were heat-
treated at 56C for 60 min to eliminate endogenous enzyme activity, mixed with an equal 
volume of intact normal pooled plasma, and incubated for 2 hours at 37C. The residual 
enzyme activity is measured after incubation. One Bethesda unit is defined as the amount of 
inhibitor that reduces activity by 50% of the control value, and values greater than 0.5 U/ml 
are significant. 
6. ADAMTS13 activity and its related parameters in AH 
Plasma ADAMTS13:AC was assayed according to the method of Furlan et al. (Furlan et al., 
1996) with slight modifications (Mori et al., 2002). ADAMTS13:AC was markedly decreased 
in fatal SAH cases with multiorgan failure, in contrast to a mild-to-moderate decrease in 
SAH and AH survivors (Fig. 2a) (Uemura et al., 2005b; Matsuyama et al., 2007). 
Interestingly, ADAMTS13:AC in fatal SAH cases with multiorgan failure was extremely 
low, which is consistent with typical TTP. The VWF:AG level was remarkably increased in 
AH, especially in fatal SAH cases (Fig. 2b). Accordingly, VWF:AG relative to 
ADAMTS13:AC was extremely high in fatal SAH cases compared to AH and SAH survivors 
(Fig. 2c).  
During recovery, ADAMTS13:AC returned to a normal range, and both VWF:AG levels and 
levels of VWF:AG relative to ADAMTS13:AC decreased in AH and SAH survivors; 
however, in fatal SAH cases, the activity remained extremely low while the VWF:AG levels 
were still high, resulting in an extremely high ratio of VWF:AG to ADAMTS13:AC  
(Matsuyama et al., 2007; Uemura et al., 2005b). These results suggest that plasma 
ADAMTS13:AC and its substrate, VWF:AG, are closely correlated with the severity of liver 
disturbance and may be useful markers for predicting the clinical outcome of AH, especially 
in SAH with multiorgan failure. Indeed, the prognosis was very poor in three SAH patients 
with extremely low ADAMTS13:AC and markedly high VWF:Ag. Furthermore, cirrhotic 
patients with superimposed AH showed higher levels of VWF:Ag (576% vs. 303%, p<0.005) 
and VWF:Ag relative to ADAMTS13:AC (14.0 vs. 5.3, p<0.01) than those with AH without 
LC, indicating that cirrhotic patients with superimposed AH may be a high risk for hepatic  
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Fig. 2. Plasma values of ADAMTS13:AC, VWF:Ag, and the ratio of VWF:Ag to 
ADAMTS13:AC in the patients with AH, SAH, and alcoholic LC.  
ADAMTS13:AC was significantly lower in AH, SAH and LC patients than in healthy 
subjects (a). The activity further decreased in the patients with SAH compared to those with 
AH and LC. In three fatal SAH cases, ADAMTS13:AC was extremely low. VWF:Ag was 
significantly higher in AH, SAH and LC patients than in healthy subjects (b). The antigen 
further increased in SAH patients compared to AH patients. In the three fatal SAH patients, 
VWF:Ag was extremely high. VWF:Ag relative to ADAMTS13 activity was markedly higher 
in AH, SAH and LC patients than in healthy subjects (c). It further increased in patients with 
SAH compared to those with AH and LC. In the three fatal SAH cases, it was extremely 
high. The dotted lines show the upper limit of the normal range, and dot-dashed lines the 
lower limit of the normal range. The normal range was 102±23% (mean±2SD, n=60) in 
ADAMTS13:AC, 100±53% in VWF:Ag, and 1.0 ± 0.4 for the ratio of VWF:Ag to 
ADAMTS13:AC, respectively. Open and shaded circles indicate survivors and the closed 
circles indicate non-survivors. The shaded circles show alcoholic LC with superimposed 
AH. AH=alcoholic hepatitis, SAH=severe alcoholic hepatitis, LC=alcoholic liver cirrhosis, 
ADAMTS13:AC=ADAMTS13 activity, VWF:Ag=von Willebrand factor antigen, 
VWF:Ag/ADAMTS13:AC=the ratio of VWF antigen to ADAMTS13 activity. *p<0.05, 
**p<0.01, and ***p<0.005 significantly different between the two groups. (Partially modified 
from Uemura et al., 2005b and Matsuyama et al., 2007).  
failure (Matsuyama et al., 2007; Uemura et al., 2005b). In addition, in LC patients, 
ADAMTS13:AC tended to be lower as the cirrhotic stage progressed, suggesting that 
decreased ADAMTS13:AC is related to the functional liver capacity. Similar findings that 
ADAMTS13:AC decreases with increasing cirrhosis severity was recently reported (Feys et 
al., 2007; Uemura et al., 2008a). 
In an univariate analysis ADAMTS13:AC was significantly correlated with 10 clinical 
variables, including functional liver capacity, inflammation signs, renal function, and 
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platelet counts (Uemura et al., 2005b, 2008b) . VWF:Ag was significantly correlated with 
nine clinical variables, including functional liver capacity, anemia, inflammation signs, and 
platelet counts (Matsuyama et al., 2007; Uemura et al., 2008b). The factors associated with 
decreased ADAMTS13:AC and increased VWF:Ag, reduced functional liver capacity, 
augmented inflammation, and thrombocytopenia are consistent with the clinical 
characteristics that frequently appear in AH and SAH (Fujimoto et al., 1999; Haber et al., 
2003; Ishii et al., 1993; Maddrey et al., 1978; McClain et al., 1999; Mookerjee et al., 2003). 
Remarkably, the imbalance between the ADAMTS13:AC and VWF:Ag levels might provide 
another mechanism for thrombocytopenia that usually occurs in AH even in the absence of 
signs of apparent disseminated intravascular coagulation (DIC). 
On admission, UL-VWFM was detected in 4 (80.0%) of 5 SAH patients and in 5 (55.6% ) of 9 
AH patients, whose ADAMTS13:AC was less than 50% of normal control plasma levels (Fig. 
3a) (Matsuyama et al., 2007). UL-VWFM-positive patients showed lower ADAMTS13:AC, 
higher plasma VWF:Ag, and a higher ratio of VWF:Ag to ADAMTS13:AC than UL-VWFM-
negative patients (mean ADAMTS13:AC = 22% vs. 43%, p<0.02; VWF:Ag = 724% vs. 372 %, 
p<0.05; the ratio of VWF:Ag to ADAMTS13:AC = 66.0 vs. 8.2, p<0.01, respectively). In 
particular, UL-VWFM was detected in three fatal SAH patients with multiorgan failure 
(cases 1, 2, and 3, Fig. 3a) (Matsuyama et al., 2007). These findings of enhanced UL-VWFM 
production with deficient ADAMTS13 activity may, in part, contribute not only to the 
development of multiorgan failure but also to the progression of liver injury through 
microcirculatory disturbances in AH. Our results suggest an additional mechanism to 
explain multiorgan failure with liver disturbance, particularly in SAH patients. In order to 
confirm a TTP-like phenomenon as described above, it will be necessary to confirm the 
presence or absence of the platelet thrombi using samples obtained from liver and other 
organs in SAH patients. 
 
 
 
 
 
 
 
 
 
 
Fig. 3. The VWF multimer analysis and the difference in endotoxin level between UL-
VWFM positive and negative patients in AH and SAH patients on admission.  
UL-VWFM was detected in 4 of 5 SAH patients (80.0%, cases 1, 2, 3, and 5), and 3 of these 
patients died of hepatic failure with multiorgan failure (cases 1, 2 and 3) (a). In addition, UL-
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VWFM was detected in 5 of 9 AH patients (55.6%, cases 6, 7, 8, 10, and 11), who had a 
moderate ADAMTS13 deficiency together with markedly high VWF:AG values (a). Plasma 
endotoxin concentrations were higher in UL-VWFM positive patients than UL-VWFM 
negative ones (b). AH=alcoholic hepatitis, SAH=severe alcoholic hepatitis, ADAMTS13: 
AC=ADAMTS13 activity, VWF:Ag=von Willebrand factor antigen, UL-VWFM= unusually 
large VWF multimer, NP shows the normal control plasma. (Partially modified from 
Matsuyama et al., 2007 and Ishikawa et al., 2010). 
Hepatic microcirculatory disturbances are considered to play an important pathogenic role 
in ALD. VWF immunostaining was positive in sinusoidal lining cells and the scar-
parenchyma interface even at the early stages of ALD (Urashima et al., 1993). Deficiencies in 
plasma ADAMTS13:AC and augmented VWF production in transformed vascular ESc 
might play an important role in sinusoidal microcirculatory disturbances and subsequent 
liver injury in AH patients. Furthermore, in SAH patients mild to severe hepatic veno-
occlusive disease (VOD) was frequently observed  (Goodman & Ishak, 1982; Kishi et al., 
2000). After stem cell transplantation (SCT), plasma ADAMTS13:AC was significantly lower 
in patients with hepatic VOD than those without (Park et al., 2002). Prophylactic infusion of 
fresh frozen plasma (FFP) as a source of ADAMTS13 may be useful in preventing the 
development of hepatic VOD after SCT (Matsumoto et al., 2007), indicating a causative role 
of increased VWF production relative to decreased ADAMTS13:AC. Our present findings of 
markedly decreased ADAMTS13:AC and markedly increased VWF:AG may be involved in 
the pathogenesis of VOD in SAH patients. 
7. Potential role of decreased ADAMTS13:AC in AH 
The reason why ADAMTS13:AC decreases in AH and SAH patients remains to be clarified, 
but potential mechanisms may include: enhanced consumption due to the degradation of 
large quantities of UL-VWFM (Mannucci et al., 2001); cytokinemia- and/or endotoxemia-
induced deficiency of ADAMTS13 (Ishikawa et al., 2010); the presence of inhibitors as 
detected in the majority of patients with “idiopathic” pregnancy- or drug-associated TTP 
(Fujimura & Matsumoto, 2010; Ishikawa et al., 2010); the decreased production of 
ADAMTS13 in HSCs (Kume et al., 2007); and the direct inhibition of the protease by ethanol 
and/or its metabolites. It is controversial whether ADAMTS13 deficiency is caused by 
decreased production in the liver. Kume et al. reported that HSC apoptosis plays an 
essential role in decreased ADAMTS13:AC using dimethylnitrosamine-treated rats, but not 
carbon tetrachloride (CCl4)-treated animals (Kume et al., 2007), whereas Niiya et al. found 
upregulation of ADAMTS13 antigen and proteolytic activity in liver tissue using rats with 
CCl4-induced liver fibrosis (Niiya et al., 2006). In our study, the ADAMTS13:AC gradually 
decreased (Fig. 4, upper panels), and the VWF:Ag progressively elevated with concomitant 
increase in concentrations of IL-6, IL-8, and TNFǂ from normal range to over 100 g/mL on 
admission (Fig. 4, lower panels) (Ishikawa et al., 2010).  
The incidence of UL-VWFM detected in plasma became higher as concentrations of IL-6, IL-
8, and TNFǂ increased (Ishikawa et al., 2010). At the recovery stage in survivors with AH 
and SAH, the ADAMTS13:AC increased to normal range, the VWF:Ag decreased, and the 
UL-VWFM disappeared with the decrease in the concentration of IL-6 and IL-8, whereas in a 
non-survivor with SAH, the ADAMTS13:AC remained at extremely low levels, the VWF:Ag 
was still high, and the UL-VWFM was persistently present with the increase in  
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Fig. 4. Relation of plasma cytokine levels to ADAMTS13:AC and VWF:Ag in AH and SAH 
patients on admissionin.  
ADAMTS13:AC concomitantly decreased with increasing concentrations of plasma IL-6 and 
IL-8, and the activity decreased in patients with TNFǂ concentrations higher than the 
normal range compared to those without (upper panels). On the other hand, VWF:Ag 
concomitantly increased with increasing concentrations of plasma IL-6 and IL-8, and the 
values increased in patients with TNFǂ concentration higher than the normal range 
compared to those without (lower panels). Shaded area shows normal ranges. IL-6= 
interleukin 6, IL-8=interleukin 8, TNFǂ=tumor necrosis factor ǂ, N=normal range. *p<0.05,  
**p<0.005, and ***p<0.001 significantly different between the two groups. 
ADAMTS13:AC=ADAMTS13 activity, VWF:Ag=von Willebrand factor antigen. (Partially 
modified from Ishikawa et al., 2010).  
concentrations of these cytokines (Ishikawa et al., 2010). These results indicate that the 
decrease in the ADAMTS13:AC and the increase in VWF:Ag in addition to UL-VWFM may 
be closely associated with increased proinflammatory cytokines including IL-6, IL-8, and 
TNFǂ. Recently, it was demonstrated that IL-6 inhibited the action of ADAMTS13 under 
flow condition, and both IL-8 and TNFǂ stimulated the release of UL-VWFM using human 
umbilical vein ECs (Bernardo et al., 2004). IFN-Ǆ, IL-4, and TNFǂ also inhibit ADAMTS13 
synthesis and activity in rat primary HSCs (Cao et al., 2008). Additionally, inflammation-
associated ADAMTS13 deficiency promotes formation of UL-VWFM (Bockmeyer et al., 
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2008; Claus et al., 2010). However, it is unknown whether IL-6 directly hampers the cleavage 
of UL-VWFM or if IL-6 down-regulates gene expression of ADAMTS13 whereby modifying 
the promoter activity. 
Our study shows that plasma endotoxin concentration determined by a chromogenic 
substrate assay (Obayashi et al., 1984; Obayashi et al., 1985) was higher in patients with SAH 
and AH than in healthy subjects, and was markedly higher in patients with SAH than in AH 
(Fig. 5a) (Ishikawa et al., 2010). Our results are consistent with data previously reported 
(Fujimoto et al., 2000; Fukui et al., 1991; Fukui, 2005) most likely due to hepatic 
reticuloendothelial dysfunction and increased intestinal permeability caused by the opening 
of intestinal tight junctions by alcohol and its metabolite (Purohit et al., 2008). Upon 
admission, the endotoxin concentration correlated inversely with ADAMTS13 activity (Fig. 
5b, upper panel), and positively with VWF:Ag (Fig. 5b, lower panel), and was higher in 
patients with UL-VWFM than those without (Fig. 3b). At the recovery stage, the endotoxin 
concentration decreased with the increase in ADAMTS13:AC and the decrease in VWF:Ag, 
and the disappearance of UL-VWFM together with the reduction of IL-6 and IL-8 
concentrations (Ishikawa et al., 2010). These results indicate that enhanced endotoxemia  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Plasma endotoxin concentration and relation of endotoxin to ADAMTS13:AC and 
VWF:Ag in patients with alcoholic hepatitis. 
Upon admission, plasma endotoxin concentrations were higher in patients with AH and 
SAH than in normal subjects, and the values were higher in SAH patients compared to AH 
(a). In addition, the endotoxin concentration correlated inversely with ADAMTS13:AC  
(r= - 0.474, p<0.01) (b, upper panel), and positively with VWF:Ag (r= - 0.406, p<0.05) (b, 
lower panel). N=normal healthy control, AH=alcoholic hepatitis, SAH=severe alcoholic 
hepatitis, ADAMTS13:AC=ADAMTS13 activity, VWF:Ag=von Willebrand factor antigen. 
Open circles indicate survivors, and closed circles nonsurvivors. Shaded area shows normal 
range. (Partially modified from Ishikawa et al., 2010). 
www.intechopen.com
Crucial Role of ADAMTS13 Related to Endotoxemia and  
Subsequent Cytokinemia in the Progression of Alcoholic Hepatitis 
 
191 
may be closely related to the decrease in the ADAMTS13:AC and the appearance of UL-
VWFM through the enhanced cytokinemia, leading to systemic microcirculatory 
disturbances and multiorgan failure, particularly in SAH patients. Intravenous infusion of 
endotoxin to healthy volunteers caused a decrease in plasma ADAMTS13:AC together with 
the appearance of UL-VWFM (Reiter et al., 2005). Severe secondary ADAMTS13 deficiency 
can be associated with sepsis-induced DIC and may contribute to the development of renal 
failure (Ono et al., 2006). These  observations may support our data and hypothesis. 
In response to alcohol intake, innate immune cells initiate and maintain hepatic 
inflammation via pattern recognition receptors, toll-like receptor 4 (TLR4) (Akira et al., 2006; 
Szabo, 1999). The TLR4 involves the co-receptors CD14 and myeloid differentiation (MD) 
protein 2 (MD2), and the LPS binding protein (LBP) (Chow et al., 1999; Visintin et al., 2001), 
which directly binds LPS and facilitates the association between LPS and CD14 (Wright et 
al., 1989). The activation of TLR4 in Kupffer cells by LPS is a key pathogenic mediator of 
ALD through production of inflammatory cytokines (TNFǂ and IL-6) and reactive oxygen 
species (Byun & Jeong, 2010; Soares et al., 2010). More recently, the disruption of interferon 
regulatory factor 3 in liver parenchymal cells has been shown to increase liver injury due to 
the deregulated expression of pro- and anti-inflammatory cytokines via Myd88-independent 
pathways (Hritz et al., 2008; Petrasek et al., 2011). It will be of particular interest to clarify 
the relation of ADAMTS13 to endotoxin-induced cytokinemia via the TLR4 signaling 
cascade in ALD.  
Alternatively, another mechanism to reduce the activity of ADAMTS13 is the action of the 
plasma inhibitor against ADAMTS13. In our study, the inhibitor was detected in 80% of 
SAH patients and 21.4% of AH patients upon admission, and its inhibitory activity averaged 
1.5 BU/ml in SAH and 1.0 BU/ml in AH (Ishikawa et al., 2010). Patients with the inhibitor 
showed lower ADAMTS13:AC and higher VWF:Ag than those without. At the recovery 
stage, the inhibitor was detected in 5 patients but disappeared with increased 
ADAMTS13:AC and decreased VWF:Ag, together with the decrease in concentrations of 
cytokines and endotoxin. Interestingly, patients with AH and SAH who had the inhibitor 
showed higher levels of serum total bilirubin, polymorphonuclear neutrophil count, plasma 
C-reactive protein, and plasma endotoxin concentration, and lower serum albumin levels 
than those with AH who had no inhibitor (Ishikawa et al., 2010). These results indicate that 
the decrease in the ADAMTS13:AC may be caused by the presence of its inhibitor, which is 
closely related to lower functional liver capacity, marked inflammation, and enhanced 
endotoxemia in patients with AH and SAH. Intravenous infusion of endotoxin to healthy 
volunteers induced the decrease in plasma ADAMTS13:AC together with the increase in 
VWF:Ag and the appearance of UL-VWFM during acute systemic inflammation (Reiter et 
al., 2005). From our results and previously reported findings (Reiter et al., 2005), 
endotoxemia itself might be a candidate to reduce plasma ADAMTS13:AC together with 
inflammatory cytokines in AH patients. It will be necessary to clarify what kinds of inhibitor 
is involved in association with inflammatory cytokines and endotoxin. Recently, we 
encountered two patient who developed TTP; one occurred in the course of hepatitis C virus 
(HCV)-related advanced LC (Yagita et al., 2005) and another occurred a month after 
pegylated-interferon alpha-2a therapy in a HCV-related case of chronic hepatitis (Kitano et 
al, 2006). In both cases, plasma ADAMTS13:AC was extremely low, and the inhibitor against 
ADAMTS13 was detected in the patient’s heated plasma (2.0 BU/ml, 1.6 BU/ml, 
respectively) and purified IgG (0.19 BU/mg IgG, 0.4 BU/mg IgG, respectively). 
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Furthermore, we could detect IgG-inhibitor by western blot in 4 patients with advanced LC, 
who showed extremely lower ADAMTS13 activity (<3% of controls), but had no apparent 
clinical features of TTP, indicating the existence of “subclinical TTP” (Uemura et al., 2008a). 
Of 108 patients with idiopathic TTP whose plasma samples were sent to our department of 
Blood Transfusion Medicine, the inhibitor was detected in 54 (79.4%) of 68 patients 
analyzed, and its inhibitor activity was 0.5 to 2.0 BU/ml in 33 cases (61.1%), and more than 
2.0 BU/ml in the remaining 21 cases (38.9%) (Matsumoto et al., 2004). Taken together, these 
observations suggest that the inhibitor activity detected in our patients with SAH and AH 
would be enough to reduce the activity of plasma ADAMTS13. 
8. Clinical significance of plasma ADAMTS13:AC determination and future 
perspective in severe liver diseases 
The introduction of ADAMTS13 to the field of hepatology not only enabled us to confirm 
the diagnosis of TTP early, but also provided novel insight into the pathophysiology of liver 
diseases. Some diseases were shown to be TTP itself, but others did not show any apparent 
clinical features of TTP, even in the presence of markedly decreased ADAMTS13:AC and 
increased UL-VWFM that correlate with TTP. Such TTP-like states, but not DIC, may 
indicate “subclinical TTP” as seen in advanced LC (Uemura et al., 2008a, Uemura et al., 
2010) and SAH patients (Matsuyama et al., 2007; Uemura et al., 2005b; Uemura et al., 2008b), 
or “local TTP” as shown in patients with hepatic VOD after SCT (Matsumoto et al., 2007; 
Park et al., 2002) and patients with adverse events after living-donor liver transplantation 
(Ko et al., 2006). One would be unable to detect such TTP-like phenomena without the 
determination of ADAMTS13:AC, because the interaction of ADAMTS13 and UL-VWFM is 
the initial step in hemostasis, and their abnormalities do occur even in the absence of 
apparent imbalance in other conventional hemostatic factors. One could, then, notice that 
the origin of VWF, the substrate of ADAMS13, is indeed transformed hepatic sinusoidal 
and/or extrahepatic ECs, but not hepatocytes.  The procoagulant and anticoagulant proteins 
synthesized in hepatocytes decrease as liver disease progresses, whereas VWF markedly 
increases. Under such circumstances, ADAMTS13 deficiency may lead to microcirculatory 
disturbances not only in the liver, but also in the systemic circulation. The determination of 
ADAMTS13 and its related parameters will thus be quite useful for better understanding the 
pathophysiology and for providing appropriate treatments especially in severe liver disease 
patients.  
Regarding FFP infusion as a unique source of ADAMTS13, we clearly showed that pre-
existing UL-VWFMs in the plasma of USS patients began to disappear within 1 hour and 
completely disappeared 24 hours after ADAMTS13 was replenished with infusions of FFP 
(Yagi et al., 2001), indicating that exogenous ADAMTS13 could efficiently cleave both UL-
VWFMs pre-existing in the circulation and the newly produced molecules at the ECs’ surface. 
Furthermore, prophylactic FFP infusion may be instrumental in preventing the development 
of hepatic VOD after SCT (Matsumoto et al., 2007). Our five patients with SAH were treated 
with FFP infusion together with supportive care, and two of them survived, but the remaining 
three did not (Ishikawa et al., 2010). One of the non-survivors showed a transient increase in 
ADAMTS13:AC during FFP infusion, which ultimately decreased. The other two patients died 
of hepatic failure (Ishikawa et al., 2010). The administration of FFP may be useful, in part, as a 
supplementation of ADAMTS13, but the effects might depend on the severity of the liver 
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disturbance, or the degree of liver regeneration and multiorgan failure in SAH patients. 
Additionally, it is extremely important to monitor plasma ADAMTS13:AC in the treatment of 
thrombocytopenia associated with allograft dysfunction after liver transplantation. This is 
because the infusions of a platelet concentrate, but not FFP, under an imbalance of decreased 
ADAMTS13:AC to enhanced UL-VWFM production, may further exacerbate the formation of 
platelet aggregates mediated by uncleaved UL-VWFM, leading to graft failure via the “local 
TTP” mechanism (Ko et al., 2006). FFP infusion as ADAMTS13 replacement therapy may 
improve both liver dysfunction and thrombocytopenia in liver transplant patients.  
From our point of view, it will be indispensable to measure ADAMTS13:AC when patients 
are encountered with unexplained thrombocytopenia in the course of liver disease.  We are 
particularly interested in the conduct of clinical trials with recombinant ADAMTS13 
preparations in severe liver diseases, including SAH, advanced LC, hepatic VOD and liver 
transplant patients. Further investigations will be necessary to define candidates for 
ADAMTS13 supplementation therapy, and to evaluate its potential therapeutic efficacy in 
severe liver diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. A working hypothesis of ADAMTS13 and its related parameters in the progression of 
alcoholic hepatitis. 
9. Conclusion 
Enhanced gut-derived endotoxemia via hepatic reticuloendothelial dysfunction and 
increased intestinal permeability and subsequent cytokinemia may result in SECs injury and 
systemic inflammatory response syndrome, leading to microcirculatory disturbance in 
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hepatic sinusoid and multiple organs, and finally, to the necrosis of hapatocytes and 
multiorgan failure in patients with AH, and particularly in patients with SAH (Fig. 6.). The 
imbalance between the enhanced production of UL-VWFM and the deficient activity of 
ADAMTS13 may, in part, contribute to not only sinusoidal microcirculatory disturbances 
and subsequent liver injury in AH, but also to the development of multiorgan failure 
through impaired organ microcirculation in SAH. Decreased ADAMTS13:AC and increased 
VWF:Ag could be induced by pro-inflammatory cytokinemia and the plasma inhibitor 
against ADAMTS13, both of which may be closely related to enhanced endotoxemia (Fig. 
6.). The determination of ADAMTS13:AC and its substrate will give us new insights into the 
pathophysiology of acute ALD and help to elucidate additional therapeutic strategies 
including ADAMTS13 supplementation for this disease. 
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